Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Rationale for the Treatment of Metastatic Neuroblastoma

A Rationale for the Treatment of Metastatic Neuroblastoma Abstract In developing a chemotherapeutic program for children with disseminated neuroblastoma, we established three human neuroblastoma lines in cell culture to study the effects of dibutyryl cyclic AMP, papaverine, 5-trifluoromethyl-2′-deoxyuridine, and cyclophosphamide on cell growth, biochemical behavior, and morphology. Based upon our studies, a clinical treatment program was designed. We have treated 15 patients with disseminated neuroblastoma and have established the optimum dose range and sequence of these drugs. Early results were promising; plans for continuation of clinical and experimental studies were discussed. 1 Presented at the Symposium on Advances in Neuroblastoma Research, held at The Children's Hospital of Philadelphia, Philadelphia, Pa., May 30, 1975. 2 Supported in part by Public Health Service grant CA08748 from the National Cancer Institute and by the Ann Marie O'Brien Neuroblastoma Research Fund. This content is only available as a PDF. Author notes 3 Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JNCI: Journal of the National Cancer Institute Oxford University Press

Loading next page...
 
/lp/oxford-university-press/a-rationale-for-the-treatment-of-metastatic-neuroblastoma-jVa7AO2u9f

References (8)

Publisher
Oxford University Press
ISSN
0027-8874
eISSN
1460-2105
DOI
10.1093/jnci/57.3.727
Publisher site
See Article on Publisher Site

Abstract

Abstract In developing a chemotherapeutic program for children with disseminated neuroblastoma, we established three human neuroblastoma lines in cell culture to study the effects of dibutyryl cyclic AMP, papaverine, 5-trifluoromethyl-2′-deoxyuridine, and cyclophosphamide on cell growth, biochemical behavior, and morphology. Based upon our studies, a clinical treatment program was designed. We have treated 15 patients with disseminated neuroblastoma and have established the optimum dose range and sequence of these drugs. Early results were promising; plans for continuation of clinical and experimental studies were discussed. 1 Presented at the Symposium on Advances in Neuroblastoma Research, held at The Children's Hospital of Philadelphia, Philadelphia, Pa., May 30, 1975. 2 Supported in part by Public Health Service grant CA08748 from the National Cancer Institute and by the Ann Marie O'Brien Neuroblastoma Research Fund. This content is only available as a PDF. Author notes 3 Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021.

Journal

JNCI: Journal of the National Cancer InstituteOxford University Press

Published: Sep 1, 1976

There are no references for this article.